Upon binding to CD155, TIGIT also suppresses NK-mediated cytotoxicity and IFN-γ production [58,74], while blocking TIGIT/CD155 interaction effectively reverses NK cells’ dysfunction and confers anti-tumor activity, even in melanoma models refractory to melanoma-associated antigen specific CD8+T-cells [75,76]. This evidence concerns the gene CD8A and melanoma.